<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals - Mbuagbaw, L - 2016 | Cochrane Library</title> <meta content="Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals - Mbuagbaw, L - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004246.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals - Mbuagbaw, L - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004246.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004246.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals" name="citation_title"/> <meta content="Lawrence Mbuagbaw" name="citation_author"/> <meta content="mbuagblc@mcmaster.ca" name="citation_author_email"/> <meta content="Sara Mursleen" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="James H Irlam" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Alicen B Spaulding" name="citation_author"/> <meta content="National Institute of Allergy and Infectious Diseases" name="citation_author_institution"/> <meta content="George W Rutherford" name="citation_author"/> <meta content="University of California, San Francisco" name="citation_author_institution"/> <meta content="Nandi Siegfried" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD004246.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/12/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004246.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004246.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004246.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alkynes; Anti-HIV Agents [therapeutic use]; Benzoxazines [adverse effects, *therapeutic use]; Cyclopropanes; Drug Therapy, Combination [methods]; HIV Infections [*drug therapy, mortality, virology]; Nevirapine [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors [adverse effects, *therapeutic use]; Viral Load [drug effects]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004246.pub4&amp;doi=10.1002/14651858.CD004246.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="XHP2gG4h";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004246\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004246\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fa"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD004246.pub4",title:"Efavirenz or nevirapine in three\\u2010drug combination therapy with two nucleoside or nucleotide\\u2010reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral\\u2010na\\u00EFve individuals",firstPublishedDate:"Dec 10, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004246.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004246.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004246.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004246.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004246.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004246.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004246.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004246.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004246.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004246.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2482 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004246.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-sec-0016"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-sec-0017"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-sec-0022"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-sec-0023"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/appendices#CD004246-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/table_n/CD004246StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/table_n/CD004246StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information#CD004246-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lawrence Mbuagbaw</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information#CD004246-cr-0003">Sara Mursleen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information#CD004246-cr-0004">James H Irlam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information#CD004246-cr-0005">Alicen B Spaulding</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information#CD004246-cr-0006">George W Rutherford</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information#CD004246-cr-0007">Nandi Siegfried</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information/en#CD004246-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 December 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004246.pub4">https://doi.org/10.1002/14651858.CD004246.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004246-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004246-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004246-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004246-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004246-abs-0001" lang="en"> <section id="CD004246-sec-0001"> <h3 class="title" id="CD004246-sec-0001">Background</h3> <p>The advent of highly active antiretroviral therapy (ART) has reduced the morbidity and mortality due to HIV infection. The World Health Organization (WHO) ART guidelines focus on three classes of antiretroviral drugs, namely nucleoside or nucleotide reverse transcriptase inhibitors (NRTI), non‐nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors. Two of the most common medications given as first‐line treatment are the NNRTIs, efavirenz (EFV) and nevirapine (NVP). It is unclear which NNRTI is more efficacious for initial therapy. This systematic review was first published in 2010. </p> </section> <section id="CD004246-sec-0002"> <h3 class="title" id="CD004246-sec-0002">Objectives</h3> <p>To determine which non‐nucleoside reverse transcriptase inhibitor, either EFV or NVP, is more effective in suppressing viral load when given in combination with two nucleoside reverse transcriptase inhibitors as part of initial antiretroviral therapy for HIV infection in adults and children. </p> </section> <section id="CD004246-sec-0003"> <h3 class="title" id="CD004246-sec-0003">Search methods</h3> <p>We attempted to identify all relevant studies, regardless of language or publication status, in electronic databases and conference proceedings up to 12 August 2016. We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov to 12 August 2016. We searched LILACS (Latin American and Caribbean Health Sciences Literature) and the Web of Science from 1996 to 12 August 2016. We checked the National Library of Medicine (NLM) Gateway from 1996 to 2009, as it was no longer available after 2009. </p> </section> <section id="CD004246-sec-0004"> <h3 class="title" id="CD004246-sec-0004">Selection criteria</h3> <p>We included all randomized controlled trials (RCTs) that compared EFV to NVP in people with HIV without prior exposure to ART, irrespective of the dosage or NRTI's given in combination. </p> <p>The primary outcome of interest was virological success. Other primary outcomes included mortality, clinical progression to AIDS, severe adverse events, and discontinuation of therapy for any reason. Secondary outcomes were change in CD4 count, treatment failure, development of ART drug resistance, and prevention of sexual transmission of HIV. </p> </section> <section id="CD004246-sec-0005"> <h3 class="title" id="CD004246-sec-0005">Data collection and analysis</h3> <p>Two review authors assessed each reference for inclusion using exclusion criteria that we had established a priori. Two review authors independently extracted data from each included trial using a standardized data extraction form. We analysed data on an intention‐to‐treat basis. We performed subgroup analyses for concurrent treatment for tuberculosis and dosage of NVP. We followed standard Cochrane methodological procedures. </p> </section> <section id="CD004246-sec-0006"> <h3 class="title" id="CD004246-sec-0006">Main results</h3> <p>Twelve RCTs, which included 3278 participants, met our inclusion criteria. None of these trials included children. The length of follow‐up time, study settings, and NRTI combination drugs varied greatly. In five included trials, participants were receiving concurrent treatment for tuberculosis. </p> <p>There was little or no difference between EFV and NVP in virological success (RR 1.04, 95% CI 0.99 to 1.09; 10 trials, 2438 participants; <i>high quality evidence</i> ), probably little or no difference in mortality (RR 0.84, 95% CI 0.59 to 1.19; 8 trials, 2317 participants; <i>moderate quality evidence</i> ) and progression to AIDS (RR 1.23, 95% CI 0.72 to 2.11; 5 trials, 2005 participants; <i>moderate quality evidence</i> ). We are uncertain whether there is a difference in all severe adverse events (RR 0.91, 95% CI 0.71 to 1.18; 8 trials, 2329 participants; <i>very low quality evidence</i> ). There is probably little or no difference in discontinuation rate (RR 0.93, 95% CI 0.69 to 1.25; 9 trials, 2384 participants; <i>moderate quality evidence</i> ) and change in CD4 count (MD −3.03; 95% CI −17.41 to 11.35; 9 trials, 1829 participants; <i>moderate quality evidence</i> ). There may be little or no difference in treatment failure (RR 0.97, 95% CI 0.76 to 1.24; 5 trials, 737 participants; <i>low quality evidence</i> ). Development of drug resistance is probably slightly less in the EFV arms (RR 0.76, 95% CI 0.60 to 0.95; 4 trials, 988 participants; <i>moderate quality evidence</i>). No studies were found that looked at sexual transmission of HIV. </p> <p>When we examined the adverse events individually, EFV probably is associated with more people with impaired mental function (7 per 1000) compared to NVP (2 per 1000; RR 4.46, 95% CI 1.65 to 12.03; 6 trials, 2049 participants; <i>moderate quality evidence</i> ) but fewer people with elevated transaminases (RR 0.52, 95% CI 0.35 to 0.78; 3 trials, 1299 participants; <i>high quality evidence</i> ), fewer people with neutropenia (RR 0.48, 95% CI 0.28 to 0.82; 3 trials, 1799 participants; <i>high quality evidence</i> ), and probably fewer people withrash (229 per 100 with NVP versus 133 per 1000 with EFV; RR 0.58, 95% CI 0.34 to 1.00; 7 trials, 2277 participants; <i>moderate quality evidence</i> ). We found that there may be little or no difference in gastrointestinal adverse events (RR 0.76, 95% CI 0.48 to 1.21; 6 trials, 2049 participants; <i>low quality evidence</i> ), pyrexia (RR 0.65, 95% CI 0.15 to 2.73; 3 trials, 1799 participants; <i>low quality evidence</i> ), raised alkaline phosphatase (RR 0.65, 95% CI 0.17 to 2.50; 1 trial, 1007 participants; <i>low quality evidence</i> ), raised amylase (RR 1.40, 95% CI 0.72 to 2.73; 2 trials, 1071 participants; <i>low quality evidence</i> ) and raised triglycerides (RR 1.10, 95% CI 0.39 to 3.13; 2 trials, 1071 participants; <i>low quality evidence</i> ). There was probably little or no difference in serum glutamic oxaloacetic transaminase (SGOT; MD 3.3, 95% CI ‐2.06 to 8.66; 1 trial, 135 participants; <i>moderate quality evidence</i> ), serum glutamic‐ pyruvic transaminase (SGPT; MD 5.7, 95% CI ‐4.23 to 15.63; 1 trial, 135 participants; <i>moderate quality evidence</i> ) and raised cholesterol (RR 6.03, 95% CI 0.75 to 48.78; 1 trial, 64 participants; <i>moderate quality evidence</i>). </p> <p>Our subgroup analyses revealed that NVP slightly increases mortality when given once daily (RR 0.34, 95% CI 0.13 to 0.90; 3 trials, 678 participants; <i>high quality evidence</i>). There were little or no differences in the primary outcomes for patients who were concurrently receiving treatment for tuberculosis. </p> </section> <section id="CD004246-sec-0007"> <h3 class="title" id="CD004246-sec-0007">Authors' conclusions</h3> <p>Both drugs have similar benefits in initial treatment of HIV infection when combined with two NRTIs. The adverse events encountered affect different systems, with EFV more likely to cause central nervous system adverse events and NVP more likely to raise transaminases, cause neutropenia and rash. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004246-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004246-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004246-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004246-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004246-abs-0003">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004246-abs-0002" lang="en"> <h3>Effectiveness of EFV compared to NVP in the suppression of HIV infection when used as part of initial three‐drug combination </h3> <p><b>Research question</b> </p> <p>For people living with HIV who have never received antiretroviral therapy (ART), which drug is more effective in suppressing HIV infection in combination with two nucleoside reverse transcriptase inhibitors (NRTI): efavirenz (EFV) or nevirapine (NVP)? </p> <p><b>Background</b> </p> <p>The introduction of highly active ART as treatment for HIV infection has greatly reduced mortality and morbidity for adults and adolescents living with HIV around the world. The recommended initial treatments for HIV infection include two drugs from a class of drugs known as NRTI and one from a related class of drugs called non‐nucleoside reverse transcriptase inhibitors (NNRTI). The two NNRTIs most commonly used are NVP and EFV. However, NVP can cause liver damage and severe rash, both of which can be fatal. EFV may also cause a rash, impair mental function, and cause foetal malformations. </p> <p><b>Main results</b> </p> <p>Cochrane researchers examined the available literature up to 12 August 2016 and identified 12 randomized controlled trials, with a total of 3278 people, that met the inclusion criteria of this review. None of the included trials included children. Four trials included people who were also receiving treatment for tuberculosis. There was little or no difference in suppression of HIV infection (<i>high quality evidence</i> ), probably little or no difference in mortality, progression to AIDS, stopping treatment early and changes in blood cells affected by HIV (<i>moderate quality evidence</i> ). There may be little or no difference in treatment failure (<i>low quality evidence</i> ). We are uncertain whether there is a difference in side‐effects (<i>very low quality evidence</i> ). No studies were found that looked at sexual transmission of HIV. Development of drug resistance is probably slightly less in the EFV group (<i>moderate quality evidence</i> ). When the side effects were examined individually, EFV probably caused more impaired mental function (6% in the EFV group and 2% in the NVP group; <i>moderate quality evidence</i> ), while NVP probably caused more people to have a rash (3% in the EFV group and 6% in the NVP group; <i>moderate quality evidence</i> ), caused more people to have reduced white blood cells (2% in the EFV group and 5% in the NVP group; <i>high quality evidence</i> ), and signs of liver damage (6% in the EFV group and 11% in the NVP group; h<i>igh quality evidence</i> ). There was probably little or no difference in increases in liver enzymes and levels of cholesterol (<i>moderate quality evidence</i> ). There may be little or no difference in digestive side‐effects, fever, enzymes from the liver and pancreas, and fat in the blood (<i>low quality evidence</i> ). People on NVP were probably more likely to die when given a once‐daily regimen (2% in the EFV group and 4% in the NVP group; <i>moderate quality evidence</i> ). In people who were taking treatment for tuberculosis compared to those who were not, there was probably little or no difference in suppression of HIV, deaths, progression to AIDS or stopping treatment early (<i>moderate to high quality evidence</i>). </p> <p><b>Conclusion</b> </p> <p>EFV and NVP are similarly effective in viral suppression, preventing HIV progression and reducing mortality. EFV is more likely to affect mental function, while NVP is more likely to cause signs of liver damage, reduced white blood cells and rash. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004246-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004246-sec-0093"></div> <h3 class="title" id="CD004246-sec-0094">Implications for practice</h3> <section id="CD004246-sec-0094"> <p>EFV and NVP provide comparable levels of viral load suppression, but have different side‐effects. Clinicians need to determine which is the more appropriate for their patients by weighing other factors like availability, pill burden, cost, and concomitant medication. They must also consider individual tolerability and watch carefully for side‐effects, some of which can be fatal. </p> <p>While subtle differences in risk of toxicity, discontinuation, and resistance may exist, we found that EFV and NVP have similar clinical efficacies. NVP given at the once daily dose of 400 mg led to higher mortality rates than EFV. </p> <p>The use of NVP or EFV in paediatric populations has not been examined in randomized controlled trials (RCTs), and all inferences need to be drawn from trials conducted in adults. </p> </section> <h3 class="title" id="CD004246-sec-0095">Implications for research</h3> <section id="CD004246-sec-0095"> <p>Although more trials would provide a more robust body of evidence, it is unlikely that additional trials will be conducted, at least in adults and adolescents. Prospective cohort studies are the most likely source of improved data on side effects, discontinuation, and development of resistance. One particular population of interest is women who have received single‐dose NVP for prevention of mother‐to‐child transmission of HIV, although the World Health Organization (WHO) no longer recommends it. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004246-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004246-sec-0016"></div> <div class="table" id="CD004246-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">'Summary of findings' table 1</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Efavirenz (600 mg) versus nevirapine (all doses) for three‐drug combination therapy with two nucleoside‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐</b> naïve<b>individuals</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> antiretroviral‐naïve individuals<br/> <b>Setting:</b> all settings<br/> <b>Intervention:</b> efavirenz 600 mg<br/> <b>Comparison:</b> nevirapine all doses (400 mg once daily and 400 mg twice daily) as part of a three‐drug combination therapy with two NRTIs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (RCTs)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with nevirapine all doses</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with efavirenz 600 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Virological success</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>688 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>715 per 1000<br/> (681 to 750) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/> (0.99 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2438<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> high<sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/> (38 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84<br/> (0.59 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2317<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>4,5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to AIDS</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<br/> (29 to 86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.23<br/> (0.72 to 2.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>5,6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All severe adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000<br/> (162 to 285) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91<br/> (0.71 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2329<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>5,7,8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000<br/> (122 to 220) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.93<br/> (0.69 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2384<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in CD4 count</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in CD4 count was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.03 lower<br/> (17.41 lower to 11.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1829<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>5,9,10,11</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>242 per 1000<br/> (189 to 309) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/> (0.76 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>737<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>12,13</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations</b>: CI: confidence interval; RR: risk ratio; OR: odds ratio; RCT: randomized controlled trial; GRADE: Grading of Recommendations Assessment, Development and Evaluation; MD: mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Three trials used a cut‐off point of 400 copies/mL (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>), but we did not downgrade for this.<br/> <sup>2</sup>Nine trials were open‐label (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), but we did not downgrade for this.<br/> <sup>3</sup>Two trials were industry‐funded (<a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), but we did not downgrade for this.<br/> <sup>4</sup>Seven trials were open‐label but we did not downgrade for this (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>).<br/> <sup>5</sup>We downgraded by 1 for imprecision due to wide CIs including appreciable harm or benefit.<br/> <sup>6</sup>Four trials were open‐labelled but we did not downgrade for this (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>)<br/> <sup>7</sup>Six trials were open‐label (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). We downgraded by 1 for this.<br/> <sup>8</sup>Trials did not report the same adverse events and used different severity scales. We downgraded by 1 for this.<br/> <sup>9</sup>Seven of the trials were open‐label but we did not downgrade for this (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>).<br/> <sup>10</sup>In one trial, the risk of bias was unclear (<a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>).<br/> <sup>11</sup>One trial had industry funding (<a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), but we did not downgrade for this.<br/> <sup>12</sup>All trials were open‐labelled but we did not downgrade for this.<br/> <sup>13</sup>Each included trial that reported this outcome defined treatment failure differently. We downgraded by 2. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004246-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">'Summary of findings' table 2</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Efavirenz (600 mg) versus nevirapine (all doses): adverse events for three‐drug combination therapy with two nucleoside‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐</b> naïve<b>individuals</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> antiretroviral‐naïve individuals<br/> <b>Setting:</b> all settings<br/> <b>Intervention:</b> efavirenz 600 mg<br/> <b>Comparison:</b> nevirapine all doses (400 mg once daily and 400 mg twice daily) as part of a three‐drug combination therapy with two NRTIs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (RCTs)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with nevirapine all doses: adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with efavirenz 600 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: central nervous system</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (2 to 18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.46<br/> (1.65 to 12.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2049<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: gastrointestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/> (9 to 22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76<br/> (0.48 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2049<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: pyrexia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.15 to 2.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1799<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: raised transaminases</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1000<br/> (90 to 201) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.52<br/> (0.35 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1299<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> high<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: raised alkaline phosphatase</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (2 to 29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.17 to 2.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1007<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: raised amylase</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (10 to 38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.40<br/> (0.72 to 2.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1071<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: raised triglycerides</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (3 to 21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10<br/> (0.39 to 3.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1071<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: neutropenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (11 to 31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.48<br/> (0.28 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1799<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> high<sup>3,8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: rash</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>229 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000<br/> (78 to 229) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/> (0.34 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2277<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>2,9</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: serum glutamic oxaloacetic transaminase (SGOT)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean severe adverse events: SGOT was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.3 higher<br/> (2.06 lower to 8.66 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: serum glutamic‐ pyruvic transaminase (SGPT)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean severe adverse events: SGPT was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 5.7 higher<br/> (4.23 lower to 15.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Raised cholesterol</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172 per 1000<br/> (21 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 6.03<br/> (0.75 to 48.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations</b>: CI: confidence interval; RR: risk ratio; OR: odds ratio; RCT: randomized controlled trial; GRADE: Grading of Recommendations Assessment, Development and Evaluation; MD: mean difference; SGOT: glutamic oxaloacetic transaminase; SGPT: serum glutamic‐ pyruvic transaminase </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Five trials (<a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>) were open‐label. One trial did not report blinding (<a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>). We downgraded by 1 for this.<br/> <sup>2</sup>We downgraded by 1 for very wide CIs.<br/> <sup>3</sup>All trials were open‐label.<br/> <sup>4</sup>Two trials (<a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>) were open label. <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a> was industry‐funded. We did not downgrade for this.<br/> <sup>5</sup>Data from one open‐label industry‐funded study (<a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). We downgraded by 1 for this.<br/> <sup>6</sup>Both trials were open‐label (<a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), but we did not downgrade for this.<br/> <sup>7</sup>Most data came from one industry‐funded trial (<a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). We downgraded one point for this.<br/> <sup>8</sup>We upgraded by 1 due to the large effect.<br/> <sup>9</sup>Six studies were open‐label (<a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>). We did not downgrade for this. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004246-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004246-sec-0017"></div> <section id="CD004246-sec-0018"> <h3 class="title" id="CD004246-sec-0018">Description of the condition</h3> <p>A total of 36.7 million people were living with HIV in 2015. This is an increase from previous years, mostly due to the use of antiretroviral therapy (ART) (<a href="./references#CD004246-bbs2-0063" title="UNAIDS . AIDS by the numbers 2015. http://www.unaids.org/sites/default/files/media_asset/AIDS‐by‐the‐numbers‐2016_en.pdf (accessed 03 November 2016). ">UNAIDS 2016</a>). In many countries, ART has reduced hospitalization, morbidity, and mortality among people living with HIV (<a href="./references#CD004246-bbs2-0048" title="GilksCF , CrowleyS , EkpiniR , GoveS , PerriensJ , SouteyrandY , et al. The WHO public‐health approach to antiretroviral treatment against HIV in resource‐limited settings. Lancet2006;368(9534):505‐10. ">Gilks 2006</a>; <a href="./references#CD004246-bbs2-0052" title="HoggRS , O'ShaughnessyMV , GataricN , YipB , CraibK , SchechterMT , et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet1997;349(9061):1294. ">Hogg 1997</a>; <a href="./references#CD004246-bbs2-0056" title="MocroftA , VellaS , BenfieldTL , ChiesiA , MillerV , GargalianosP , et al. Changing patterns of mortality across Europe in patients infected with HIV‐1. EuroSIDA Study Group. Lancet1998;352(9142):1725‐30. ">Mocroft 1998</a>). </p> <p>Significant public and private resources have been devoted to rapidly scale up efforts in low‐ and middle‐income countries (LMICs) to provide access to first‐line ART. In 2014, only 40% of eligible people in LMICs were receiving ART. These efforts to scale‐up access to ART should be accompanied by initiatives to determine the most effective first‐line therapy (<a href="./references#CD004246-bbs2-0063" title="UNAIDS . AIDS by the numbers 2015. http://www.unaids.org/sites/default/files/media_asset/AIDS‐by‐the‐numbers‐2016_en.pdf (accessed 03 November 2016). ">UNAIDS 2016</a>), which can be used in diverse populations. </p> <p>ART guidelines were first published by the World Health Organization (WHO) in 2002 (<a href="./references#CD004246-bbs2-0065" title="World Health Organization. Scaling up antiretroviral therapy in low in resource‐limited settings. Guidelines for a public health approach. June 2002. http://www.who.int/hiv/pub/prev_care/en/ScalingUp_E.pdf (accessed 03 November 2016). ">WHO 2002</a>), and were updated in 2006, 2010, 2013, 2014, and 2015 (<a href="./references#CD004246-bbs2-0070" title="World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Second edition. http://www.who.int/hiv/pub/arv/arv‐2016/en/ (accessed 03 November 2016). ">WHO 2015b</a>). For countries with limited resources, the WHO recommends a public health approach to ART to improve access, simplify clinical decision making, standardize regimens, and standardize the monitoring and management of toxicity and drug interactions (<a href="./references#CD004246-bbs2-0048" title="GilksCF , CrowleyS , EkpiniR , GoveS , PerriensJ , SouteyrandY , et al. The WHO public‐health approach to antiretroviral treatment against HIV in resource‐limited settings. Lancet2006;368(9534):505‐10. ">Gilks 2006</a>). For any initial regimen, the potency, durability of efficacy, ease of administration and storage, tolerability, and toxicity need to be balanced with cost and availability (<a href="./references#CD004246-bbs2-0048" title="GilksCF , CrowleyS , EkpiniR , GoveS , PerriensJ , SouteyrandY , et al. The WHO public‐health approach to antiretroviral treatment against HIV in resource‐limited settings. Lancet2006;368(9534):505‐10. ">Gilks 2006</a>). These guidelines provide a framework for choice of medication in most countries. However, when the recommended drugs have different costs and toxicity profiles, head‐to head comparisons are necessary to determine which medication should be the choice of preference for clinicians. The more recent guidelines integrate more evidence and are in favour of an earlier start to ART (CD4 cell count of 500 cells/mm<sup>3</sup> or less as opposed to the previous threshold of 350 cells/mm<sup>3</sup>) in active tuberculosis, hepatitis B co‐infection with severe liver disease, pregnant and breastfeeding women, children under five years of age, and sero‐discordant couples (<a href="./references#CD004246-bbs2-0068" title="World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. July 2014. http://www.who.int/hiv/pub/guidelines/keypopulations/en/ (accessed 09 September 2016). ">WHO 2014</a>). </p> </section> <section id="CD004246-sec-0019"> <h3 class="title" id="CD004246-sec-0019">Description of the intervention</h3> <p>The WHO Model List of Essential Medicines describes three classes of antiretroviral drugs for treatment and prevention of HIV infection: Nucleoside reverse transcriptase inhibitors (NRTI), non‐nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (<a href="./references#CD004246-bbs2-0069" title="World Health Organization. WHO Model List of Essential Medicines. 19th List. http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1 (accessed 10 September 2008). ">WHO 2015a</a>). In 2006 the WHO recommended that initial ART should be with one of three regimens: two NRTIs plus efavirenz (EFV), two NRTIs plus nevirapine (NVP), or two NRTIs plus abacavir (ABC) (<a href="./references#CD004246-bbs2-0048" title="GilksCF , CrowleyS , EkpiniR , GoveS , PerriensJ , SouteyrandY , et al. The WHO public‐health approach to antiretroviral treatment against HIV in resource‐limited settings. Lancet2006;368(9534):505‐10. ">Gilks 2006</a>; <a href="./references#CD004246-bbs2-0066" title="World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. http://whqlibdoc.who.int/publications/2006/9789241594677_eng.pdf (accessed 25 September 2008). ">WHO 2006</a>). ABC is not a NNRTI and didn't qualify for evaluation in this review. The NRTI combination drugs could either be zidovudine (AZT) plus lamivudine (3TC), or stavudine (d4T) plus 3TC. Stavudine is no longer recommended as a first‐line regimen, given its known metabolic toxicities and should be used only when no other drug can be offered (<a href="./references#CD004246-bbs2-0070" title="World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Second edition. http://www.who.int/hiv/pub/arv/arv‐2016/en/ (accessed 03 November 2016). ">WHO 2015b</a>). The current recommendations suggest that the preferred first‐line regimen be composed of tenofovir (TDF) and 3TC or emcitrabine (FTC) with EFV. TDF could be replaced with AZT and EFV with NVP in the event that drugs in the preferred regimen are unavailable or contraindicated (<a href="./references#CD004246-bbs2-0070" title="World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Second edition. http://www.who.int/hiv/pub/arv/arv‐2016/en/ (accessed 03 November 2016). ">WHO 2015b</a>). Protease inhibitors can also be used in special circumstances (<a href="./references#CD004246-bbs2-0070" title="World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Second edition. http://www.who.int/hiv/pub/arv/arv‐2016/en/ (accessed 03 November 2016). ">WHO 2015b</a>). </p> </section> <section id="CD004246-sec-0020"> <h3 class="title" id="CD004246-sec-0020">How the intervention might work</h3> <p>Protease inhibitors cost more, have higher pill burdens, and have dietary constraints associated with their use. Protease inhibitors are also linked to serious long‐term metabolic disorders, most notably an increased risk of lipodystrophy and hyperlipidaemia (<a href="./references#CD004246-bbs2-0057" title="MoyleGJ . Considerations in the choice of protease inhibitor‐sparing regimens in initial therapy for HIV‐1 infection. Current Opinion in Infectious Diseases2000;13(1):19‐25. ">Moyle 2000</a>; <a href="./references#CD004246-bbs2-0040" title="BHIVA Writing Committee, BHIVA Executive Committee. Guidelines for the treatment of HIV‐infected adults with antiretroviral therapy. HIV Medicine2001;2(4):276‐313. ">BHIVA 2001</a>). Moreover, a meta‐analysis of 12 trials revealed that NNRTI‐based regimens were better than protease inhibitor‐based regimens for virologic suppression (<a href="./references#CD004246-bbs2-0041" title="Chou R , RongweiF , Huffman LH , Korthuis PT . Initial highly‐active antiretroviral therapy with a protease inhibitor versus a non‐nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta‐analyses. Lancet2006;368(9546):1503‐15. ">Chou 2006</a>). </p> <p>NNRTIs have a more favourable adverse effect profile than protease inhibitors, are cheaper, and are easier to administer. They are also more cost‐effective (<a href="./references#CD004246-bbs2-0039" title="BeckEJ , MandaliaS , YouleM , BrettleR , FisherM , GompelsM , et al. Treatment outcome and cost‐effectiveness of different highly active antiretroviral therapy regimens in the UK (1996‐2002). International Journal of STD &amp; AIDS2008;19(5):297‐304. ">Beck 2008</a>). Their main disadvantage is that a single mutation may confer resistance to the entire class of NNRTIs, since cross‐resistance among agents of this class is nearly universal (<a href="./references#CD004246-bbs2-0043" title="DeeksSG . International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. Journal of Acquired Immune Deficiency Syndromes2001;26 Suppl 1:S25‐33. ">Deeks 2001</a>; <a href="./references#CD004246-bbs2-0046" title="DybulM , FauciAS , BartlettJG , KaplanJE , PauAK , Panel on Clinical Practices for the Treatment of HIV. Guidelines for using antiretroviral agents among HIV‐infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. Morbidity and Mortality Weekly Report2002;51(RR‐7):1‐55. ">Dybul 2002</a>). </p> <p>NVP may be responsible for severe or fatal hepatotoxicity, and a rash which may present in severe form as Stevens‐Johnson syndrome. Nevertheless, NVP is the NNRTI of choice for pregnant women because EFV may be teratogenic(<a href="./references#CD004246-bbs2-0044" title="Department of Health and Human Sciences. AIDSinfo Drug Database. https://aidsinfo.nih.gov/drugs/116/nevirapine/0/professional (accessed 10 November 2016). ">DHHS 2001a</a>). EFV may cause a rash and central nervous system symptoms such as dizziness, somnolence, insomnia, drowsiness, nightmares, hallucinations, and poor concentration (<a href="./references#CD004246-bbs2-0045" title="Department of Health and Human Sciences. AIDSinfo Drug Database. https://aidsinfo.nih.gov/drugs/269/efavirenz/0/professional (accessed 10 November 2016). ">DHHS 2001b</a>). </p> </section> <section id="CD004246-sec-0021"> <h3 class="title" id="CD004246-sec-0021">Why it is important to do this review</h3> <p>Providing evidence on the more appropriate choice of NNRTI with respect to efficacy, durability, and tolerability, is important to patients, caregivers, and policymakers worldwide. In the previous version of our review we found that EFV and NVP had similar efficacies, but different toxicity profiles (<a href="./references#CD004246-bbs2-0072" title="MbuagbawLC , IrlamJH , SpauldingA , RutherfordGW , SiegfriedN . Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD004246.pub3] ">Mbuagbaw 2010</a>). </p> <p>The current review update represents a collaborative effort between the Cochrane Infectious Diseases Group, the University of California, San Francisco (UCSF), the School of Public Health of the University of Minnesota, the U.S. Centers for Disease Control and Prevention (CDC), the University of Cape Town, and the WHO to address questions through systematic reviews regarding the optimum first‐line ART regimen in patients living with HIV in low‐ and middle‐income countries. The previous review was used in the development of the 2009 WHO ART treatment guidelines (<a href="./references#CD004246-bbs2-0067" title="World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. November 2009. http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf (accessed 03 November 2016). ">WHO 2009</a>). </p> <p>In the past five years, the body of evidence on NNRTI's has grown, especially among people co‐infected with tuberculosis. This Cochrane Review update responds to the need for evidence‐based recommendations for managing HIV and tuberculosis co‐morbidity. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004246-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004246-sec-0022"></div> <p>To determine which non‐nucleoside reverse transcriptase inhibitor, either EFV or NVP, is more effective in suppressing viral load when given in combination with two nucleoside reverse transcriptase inhibitors as part of initial antiretroviral therapy for HIV infection in adults and children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004246-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004246-sec-0023"></div> <section id="CD004246-sec-0024"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004246-sec-0025"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs)</p> </section> <section id="CD004246-sec-0026"> <h4 class="title">Types of participants</h4> <p>We included adults and children infected with HIV and without prior exposure to antiretroviral therapy (ART), and women who had received short courses of NNRTIs for the prevention of mother‐to‐child transmission. We excluded pregnant or lactating women and children under five years of age. </p> <p>Relevant subpopulations of interest were participants with the following:</p> <p> <ul id="CD004246-list-0001"> <li> <p>concurrent hepatitis B virus infection;</p> </li> <li> <p>concurrent hepatitis C virus infection;</p> </li> <li> <p>concurrent tuberculosis.</p> </li> </ul> </p> </section> <section id="CD004246-sec-0027"> <h4 class="title">Types of interventions</h4> <p>We considered triple‐drug antiretroviral combination regimens for initial therapy containing two NRTIs plus either EFV or NVP at any dose (EFV + 2NRTIs versus NVP + 2NRTIs). The NRTIs in each combination did not need to be specified, but if they were specified, they must have been the same in both the EFV and NVP arms, such that the only difference in the regimens was the NNRTI. We included trials with additional trial arms, but we only evaluated the EFV‐containing and NVP‐containing trial arms in this review. </p> <p>We compared EFV‐containing and NVP‐containing triple‐drug regimens with regard to therapeutic efficacy, using plasma HIV ribonucleic acid (RNA) concentration as a surrogate marker for clinical progression. Plasma HIV RNA has been demonstrated to be a reliable predictor of HIV disease progression (<a href="./references#CD004246-bbs2-0054" title="LauB , GangeS , KirkG , MehtaS , MerrimanB , MooreR . Predictive value of plasma HIV RNA levels for rate of CD4 decline and clinical disease progression. 14th Conference on Retroviruses and Opportunistic Infections (CROI); 25‐28 February, 2007; Los Angeles, California. 2007, issue Abstract 140 (oral). ">Lau 2007</a>; <a href="./references#CD004246-bbs2-0055" title="MellorsJ , MargolickJ , PhairJ , RinaldoC , DetelsR , JaconsonL , et al. Comparison of plasma HIV‐1 RNA, CD4 cell count, and CD38 expression on CD8 T cells as predictors of progression to AIDS and CD4 cell decline among untreated participants in the multicenter AIDS cohort study. 14th Conference on Retroviruses and Opportunistic Infections; 25‐28 February, 2007; Los Angeles, California. 2007. ">Mellors 2007</a>). </p> <p>An earlier Cochrane review of stavudine (d4T), lamivudine (3TC) and NVP, <a href="./references#CD004246-bbs2-0062" title="SiegfriedNL , VanDeventerPJU , MahomedFA , RutherfordGW . Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD004535.pub2] ">Siegfried 2006</a>, analysed studies that compared this regimen to any other available regimen used in the treatment of HIV/AIDS in treatment‐naïve or previously‐treated adults and adolescents. We included one trial in this review, <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>, which was also included in <a href="./references#CD004246-bbs2-0062" title="SiegfriedNL , VanDeventerPJU , MahomedFA , RutherfordGW . Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD004535.pub2] ">Siegfried 2006</a> as it compared this regimen to another that contained d4T, 3TC, and EFV in participants who had never received ART. </p> <p>We planned to extract data from trials that included participants irrespective of their exposure to ART, but provided separate reporting and analysis of the ART‐naïve group. By so doing, we could analyse the data for participants of interest from papers that included both ART‐naïve and ART‐exposed populations. </p> </section> <section id="CD004246-sec-0028"> <h4 class="title">Types of outcome measures</h4> <section id="CD004246-sec-0029"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD004246-list-0002"> <li> <p>The percentage of participants achieving undetectable plasma HIV RNA concentration (viral load) over time (virological success). For this outcome we used the lower limit of HIV RNA detection, and the time frame reported by the trial authors. </p> </li> <li> <p>Mortality.</p> </li> <li> <p>Progression to AIDS (clinical). We assessed clinical progression by the proportion of participants that progressed either to the Centers for Disease Control and Prevention (CDC)‐defined AIDS (stage III to stage IV disease) or who developed a second opportunistic infection or malignancy. </p> </li> <li> <p>All severe adverse events. We classified these according to grade 1 to 4 of the Adverse Event Toxicity Scale (<a href="./references#CD004246-bbs2-0058" title="Division ofAIDS , National Institute of Allergy and Infectious Diseases, National Institutes of Health. Table for Grading the Severity of Adult and Pediatric Adverse Events. Bethesda, Maryland: National Institutes of Health, 2004. ">NIAID/NIH 2004</a>), and reported them as the proportion of participants that experienced grade 3 and 4 clinical or laboratory adverse events. Using this scale, grade 1 and 2 denote mild to moderate symptoms, grade 3 denotes serious symptoms, and grade 4 denotes life‐threatening events requiring significant clinical intervention. </p> </li> <li> <p>Discontinuation rate. We defined this variable as the proportion of study participants who either stopped their treatment regimens totally or switched for any reason associated with the regimen. </p> </li> </ul> </p> </section> <section id="CD004246-sec-0030"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD004246-list-0003"> <li> <p>Change in mean CD4 cell count (immunological response).</p> </li> <li> <p>Treatment failure. We defined this variable as the proportion of participants with incomplete viral load suppression or who experienced a virological rebound in the time frame reported by the trial authors. </p> </li> <li> <p>Prevention of sexual transmission of HIV. We defined this as the risk of sexual partners not acquiring HIV from the study participant. </p> </li> <li> <p>Development of ART drug resistance. We defined this as the acquisition of major genotypic resistance mutations as reported by the trial authors. </p> </li> <li> <p>Individual adverse events</p> </li> </ul> </p> </section> </section> </section> <section id="CD004246-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed the literature searches with the assistance of the HIV/AIDS Review Group Information Specialist. We formulated a comprehensive and exhaustive search strategy in an attempt to identify all relevant studies, regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD004246-sec-0032"> <h4 class="title">Electronic searches</h4> <p>Our initial search included the following electronic databases.</p> <p> <ul id="CD004246-list-0004"> <li> <p>MEDLINE from 1996 to 12 August 2016 (<a href="./appendices#CD004246-sec-0099">Appendix 1</a>). </p> </li> <li> <p>Embase from 1996 to 12 August 2016 (<a href="./appendices#CD004246-sec-0100">Appendix 2</a>). </p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) from 1996 to 12 August 2016 (<a href="./appendices#CD004246-sec-0101">Appendix 3</a>). </p> </li> <li> <p>National Library of Medicine (NLM) Gateway from 1996 to 2009 (<a href="./appendices#CD004246-sec-0102">Appendix 4</a>). </p> </li> <li> <p>The World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov for ongoing trials (inception to 12 August 2016). </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Sciences Literature) from 1996 to 12 August 2016. </p> </li> <li> <p>Web of Science from 1996 to 12 August 2016.</p> </li> </ul> </p> <p>The search strategy included text terms such as efavirenz, EFV, EFZ , Sustiva, Stocrin, nevirapine, NVP, Viramune, Nevimune, non‐nucleoside reverse transcriptase inhibitor, NNRTI, protease inhibitor‐sparing, non‐protease inhibitor‐ containing. </p> </section> <section id="CD004246-sec-0033"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference lists of all pertinent reviews and studies found. We contacted research organizations and experts in the field for unpublished and ongoing studies. We conducted literature searches from 1996 to 2016 the years during which NNRTIs have been approved and been available on the market. </p> <section id="CD004246-sec-0034"> <h5 class="title">Limits</h5> <p>We performed the literature searches without limits to language or setting. The searches were limited to human studies published from 1996 (start of the triple‐drug combination ART era) to the present. </p> </section> <section id="CD004246-sec-0035"> <h5 class="title">Inclusion criteria</h5> <p> <ul id="CD004246-list-0005"> <li> <p>RCTs</p> </li> <li> <p>Trials evaluating first‐line ART regimens that compared EFV to NVP as part of a three‐drug treatment regimen. </p> </li> <li> <p>Trials that provided sufficient regimen‐specific information (dosage, presentation, NRTI combination drugs) about first‐line drugs to compare regimens and outcomes of interest. </p> </li> </ul> </p> </section> <section id="CD004246-sec-0036"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD004246-list-0006"> <li> <p>Non‐RCTs.</p> </li> <li> <p>Studies evaluating first‐line single or double antiretroviral regimens.</p> </li> <li> <p>Studies evaluating first‐line ART with more than three antiretroviral drugs.</p> </li> </ul> </p> </section> </section> </section> <section id="CD004246-sec-0037"> <h3 class="title" id="CD004246-sec-0037">Data collection and analysis</h3> <section id="CD004246-sec-0038"> <h4 class="title">Selection of studies</h4> <p>At least two review authors screened all identified citations from the literature search results by title/abstract to identify articles for inclusion in the review (LM, SM, JI, AS, NS). We retrieved the full‐text articles of citations that potentially met the inclusion criteria of the review. We assessed the articles for inclusion based on study design, types of participants, interventions, and outcome measures. We resolved any disagreements by discussion or by consulting a third review author. If we were unable to resolve disagreements because we required further information, we allocated the study to the list of studies awaiting classification. We listed all excluded studies and the reasons for exclusion in a '<a href="./references#CD004246-sec-0114" title="">Characteristics of excluded studies</a>' table. In addition, we constructed a PRISMA flow diagram to illustrate the study selection process (<a href="#CD004246-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD004246-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of study screening and selection" data-id="CD004246-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of study screening and selection</p> </div> </div> </div> </section> <section id="CD004246-sec-0039"> <h4 class="title">Data extraction and management</h4> <p>We designed and tested a data extraction form. Two review authors independently extracted data from each included trial using the data extraction form (AS, LM, SM). Both review authors verified the extracted data, which included methods, participant characteristics, interventions, and outcomes. Both review authors then compared the extracted data and resolved any discrepancies by discussion. In the event that the review authors disagreed on the abstraction of study details, we contacted a third review author to resolve the disagreement. We attempted to contact the principal investigators of the included trials in the case of any missing data or if we required clarification about the included trials. </p> </section> <section id="CD004246-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias by the following criteria.</p> <p> <ul id="CD004246-list-0007"> <li> <p>Sequence generation: how the allocation sequence was generated and whether it was adequate. </p> </li> <li> <p>Allocation concealment: how the allocation sequence was concealed and whether it was adequate. </p> </li> <li> <p>Blinding of participants, personnel, and outcome assessors.</p> </li> <li> <p>The description of the completeness of outcome data for each main outcome.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other potential sources of bias (for example, funding).</p> </li> <li> <p>Baseline data reported.</p> </li> </ul> </p> <p>We rated studies as being at either high, low, or unclear risk of bias. At least two review authors independently completed the 'Risk of bias' tables (see <a href="./appendices#CD004246-sec-0103">Appendix 5</a>). </p> </section> <section id="CD004246-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <p>We used Review Manager (RevMan) 5 for statistical analyses (<a href="./references#CD004246-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We presented the results with 95% confidence intervals (CIs). We calculated the risk ratio (RR) and the odds ratio (OR) for binary data, the weighted mean difference (WMD) for continuous data measured on the same scale, and the standardized mean difference (SMD) for continuous data measured on different scales. </p> </section> <section id="CD004246-sec-0042"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant.</p> </section> <section id="CD004246-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>We analysed the data according to the intention‐to‐treat (ITT) principle, with participants analysed in the groups to which they were randomized. We did not make any assumptions regarding the outcomes of participants who were lost to follow‐up and we conducted complete case analyses. We also attempted to contact the trial authors for missing data. </p> </section> <section id="CD004246-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity by inspecting the forest plots for overlap in the confidence intervals (CIs) and by applying the Chi<sup>2</sup> test of homogeneity (P &lt; 0.10 was the threshold for statistical significance) and the I<sup>2</sup> statistic, with values of less than 50% denoting moderate heterogeneity. </p> </section> <section id="CD004246-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>We used funnel plots to explore publication bias.</p> </section> <section id="CD004246-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We analysed the data using RevMan 5 (<a href="./references#CD004246-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used a random‐effect model to account for heterogeneity. </p> </section> <section id="CD004246-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>First we assessed the included trials for clinical heterogeneity. If we found that trials were similar enough to combine, we performed a meta‐analysis and assessed statistical heterogeneity. If there was significant unexplained statistical heterogeneity, we conducted a meta‐analysis using a random‐effects model. </p> <p>If there was clinical heterogeneity and the data were available, we planned to explore this using the following subgroup analyses: age (children/adolescents/adults), sex (male/ female), baseline CD4 count, dosage, concurrent illness (hepatitis, tuberculosis) and study design. The efficacy of NVP may be associated with dosage (<a href="./references#CD004246-bbs2-0064" title="VeldkampAI , WeverlingGJ , LangeJM , MontanerJS , ReissP , CooperDA , et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV‐1‐infected individuals. AIDS2001;15(9):1089‐95. ">Veldkamp 2001</a>). </p> <p>For the purposes of this Cochrane Review, undetectable plasma HIV RNA (viral load) served as the primary endpoint. For the meta‐analyses, we defined an undetectable viral load as less than 500 copies/mL cut‐off, in order to include as many trials as possible. </p> </section> <section id="CD004246-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We pooled the results from the included trials to determine the RR of achieving undetectable viral load. We planned to perform a sensitivity analysis to evaluate bias introduced by variability in study design, threshold of undetectable viral load, and specification of the two NRTIs. Finally, we conducted a test for homogeneity to ensure that the differences among the results of each trial could be expected by chance. We also performed a sensitivity analysis for studies with a high risk of bias. </p> <p>When interventions and study populations were sufficiently similar across different studies, we pooled the outcomes and examined the differences between the two models using both fixed‐effect and random‐effects models. Since there were no significant differences between the two models, we presented the final results using a random‐effects model. </p> <section id="CD004246-sec-0049"> <h5 class="title">Quality of the evidence</h5> <p>We assessed the quality of the body of evidence using the GRADE approach (<a href="./references#CD004246-bbs2-0050" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐Ytter , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>), which defines the quality of evidence for each outcome as the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest (<a href="./references#CD004246-bbs2-0051" title="HigginsJPT , GreenS , editor(s) . In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley &amp; Sons, 2008. ">Higgins 2008</a>). The quality rating across studies has four levels: high, moderate, low, or very low. RCTs are categorized as high quality but can be downgraded; similarly, other types of controlled trials and observational studies are categorized as low quality but can be upgraded. Factors that decrease the quality of evidence include limitations in design, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision of results, or high probability of publication bias. Factors that can increase the quality level of a body of evidence include having a large magnitude of effect, whether plausible confounding would reduce a demonstrated effect, and if there is a dose‐response gradient. We used GRADEpro Guideline Development Tool (GDT) to construct 'Summary of findings' tables (<a href="./references#CD004246-bbs2-0049" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version (assessed 03 November 2016). Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro 2014</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004246-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004246-sec-0050"></div> <section id="CD004246-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD004246-sec-0052"> <h4 class="title">Results of the search</h4> <p>We conducted the literature searches up to 12 August 2016, which yielded an additional 1232 titles. Three review authors (LM, AS, and GR) independently screened the titles, abstracts, and descriptor terms of all downloaded material from the electronic searches to identify potentially relevant studies. We discarded reports that were irrelevant to this Cochrane Review, and we obtained the full‐text articles of all potentially relevant or uncertain reports. Three review authors (LM, AS and GR) independently assessed the full‐text articles. A fourth review author, NS, acted as arbiter where there was disagreement. The review authors LM, AS, GR, and JI independently extracted data from trials that met the inclusion criteria. Finally, where resolution was not possible because we required further information, we assigned the study to the list of those awaiting classification. We attempted to contact the trial authors for further clarification of data. We had previously identified seven randomized trials as meeting inclusion criteria. From the updated searches, we screened 1176 articles for eligibility after removal of duplicates. Agreement on screening for full text appraisal in this update was moderate (Ƙ 0.52; 95% CI 0.26 to 0.76; P &lt; 0.001). We selected 16 full‐text articles for detailed appraisal, of which we identified six new studies. Agreement on inclusion/exclusion in this update was very good (Ƙ 0.86; 85% CI 0.59 to 1.00; P &lt; 0.001) One of these was the full text publication of a study previously included as an abstract (<a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>), so only five trials were newly published studies, giving a total of 12 studies. We have presented a PRISMA diagram, which illustrates the study selection process, in <a href="#CD004246-fig-0001">Figure 1</a>. </p> </section> <section id="CD004246-sec-0053"> <h4 class="title">Included studies</h4> <p>Twelve trials met the inclusion criteria of this Cochrane Review. We included seven RCTs in <a href="./references#CD004246-bbs2-0072" title="MbuagbawLC , IrlamJH , SpauldingA , RutherfordGW , SiegfriedN . Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD004246.pub3] ">Mbuagbaw 2010</a>, the previous version of this review (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). In this review update five articles that reported on five trials met the inclusion criteria (<a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>). The findings reported here are from published papers. </p> <p>See the '<a href="./references#CD004246-sec-0113" title="">Characteristics of included studies</a>' table. </p> <section id="CD004246-sec-0054"> <h5 class="title">Locations</h5> <p>One trial was a multinational trial that included 17 countries (<a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). Five trials were conducted in Africa: one in Botswana (<a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>), one in Mozambique (<a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>), one in Burkina Faso (<a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>), one in Senegal (<a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>), and one in both Senegal and Cameroon (<a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>). There were two trials from India (<a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>) and one trial each: from Mexico (<a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>), Spain (<a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>), Thailand (<a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>), and the USA (<a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>). </p> </section> <section id="CD004246-sec-0055"> <h5 class="title">Interventions</h5> <p>All included trials used EFV 600 mg and compared it to either NVP 400 mg once daily (<a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), or NVP 200 mg twice daily (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>). The 2NN trial, <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>, had trial arms that used NVP 400 mg once daily and NVP 200 mg twice daily. </p> </section> <section id="CD004246-sec-0056"> <h5 class="title">Outcomes</h5> <p>Ten trials reported virological success (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). Eight trials reported mortality (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). Five trials reported progression to AIDS (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). Eight trials reported adverse events (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). Nine trials reported a discontinuation rate (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). Nine trials reported change in CD4 count (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). Five trials reported treatment failure (<a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), and four reported development of drug resistance (<a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>). None of the included trials reported on sexual transmission of HIV. </p> </section> <section id="CD004246-sec-0057"> <h5 class="title">Co‐morbidities</h5> <p>In five included trials, the participants were concurrently receiving treatment for tuberculosis (<a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>). Only one trial reported baseline co‐infection with hepatitis B and C virus (<a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). </p> </section> <section id="CD004246-sec-0058"> <h5 class="title">Length of follow‐up</h5> <p>The shortest length of follow‐up was 24 weeks (<a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>), and the longest was 156 weeks (<a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>). Five trials ran for 48 weeks (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), two trials for 96 weeks (<a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>), one for 36 weeks (<a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>), and one for 72 weeks (<a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>). </p> <p>We have provided further details on the included studies in an additional table (<a href="#CD004246-tbl-0003">Table 1</a>). </p> <div class="table" id="CD004246-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Location</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> NVP dosage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> NRTI combination drugs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Co‐infection with tuberculosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Virological success cut‐off point</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mexico</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZT 300 mg and 3TC 150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 400 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mozambique</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3TC and d4T/AZT<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cameroon and Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TDF 300 mg and FTC 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3TC 150 mg and D4T 30 or 40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Burkina Faso</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D4T and 3TC<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D4T 40 mg and DDI 400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZT, d4T, 3TC<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 400 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZT 300 mg and 3TC 150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DDI 250 mg or 400 mg and 3TC 300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC/3TC, DDI/d4T, AZT/3TC, d4T/3TC<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>North/South America, Australia, Europe, South Africa, and Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily and 400 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D4T 40 mg and 3TC 150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botswana</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZT or d4T/3TC or DDI<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Dosage not specified.<br/> Abbreviations: NRTI: Nucleoside Reverse Transcriptase Inhibitor; ART: antiretroviral therapy; AZT: zidovudine; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; DDI: didanosine; ABC: abacavir; FTC: Emtricitabine; TDF: Tenofovir. </p> </div> </div> </section> </section> <section id="CD004246-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We have provided our reasons for excluding 26 potentially relevant studies in the '<a href="./references#CD004246-sec-0114" title="">Characteristics of excluded studies</a>' table. In this update, 11/26 studies were excluded: 5 did not have the comparison of interest (<a href="./references#CD004246-bbs2-0013" title="AntelaA , IribarrenJA , MahilloB , SantosI , RiberaE , GutierrezC , et al. Final analysis of a prospective, randomized, open‐label, multicentre trial in naïve, HIV‐1‐infected patients, comparing ZDV/3TC vs d4T/ddI, plus efavirenz, nevirapine or indinavir/ritonavir (AMADEUS 01 study). International Conference on AIDS; 11‐16 July, 2004; Bangkok, Thailand. 2004; Vol. 15:Abstract no. B11920. ">Antela 2004</a>; <a href="./references#CD004246-bbs2-0021" title="HeY , LuoY , DingYL , ZhengYH , LiJ , HuangJ , et al. [Effect of highly active anti‐retroviral therapy on prevention of mother to child transmission of HIV and on infant growth and development]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2011;45(10):912‐5. [PUBMED: 22321592] ">He 2011</a>; <a href="./references#CD004246-bbs2-0030" title="MusiimeV , CookA , KayiwaJ , ZangataD , NansubugaC , ArachB , et al. Differences in body circumferences, skin‐fold thicknesses and lipid profiles among HIV‐infected African children on and not on stavudine. Journal of the International AIDS Society2012;15(Suppl 4):18290. ">Musiime 2012</a>; <a href="./references#CD004246-bbs2-0034" title="PENPACT‐1 (PENTA 9/PACTG 390) Study Team, BabikerA , Castro nee GreenH , CompagnucciA , FiscusS , GiaquintoC , et al. First‐line antiretroviral therapy with a protease inhibitor versus non‐nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV‐infected children: an open‐label, randomised phase 2/3trial. Lancet Infect Diseases2011;11(4):273‐83. ">PENPACT 2011</a>; <a href="./references#CD004246-bbs2-0035" title="PrendergastA , Bwakura‐DangarembiziMF , CookAD , Bakeera‐KitakaS , NatukundaE , Nahirya NtegeP , et al. Hospitalization for severe malnutrition among HIV‐infected children starting antiretroviral therapy. AIDS2011;25(7):951‐6. [PUBMED: 21487251] ">Prendergast 2011</a>), 4 were sub‐studies of already included studies (<a href="./references#CD004246-bbs2-0015" title="BonnetM , BaudinE , JaniIV , NunesE , VerhoustratenF , CalmyA , et al. Incidence of paradoxical tuberculosis‐associated immune reconstitution inflammatory syndrome and impact on patient outcome. PLOS ONE2013;8(12):e84585. [PUBMED: 24367678] ">Bonnet 2013b</a>; <a href="./references#CD004246-bbs2-0026" title="MankhatithamW , LueangniyomkulA , ManosuthiW . Hepatotoxicity in patients co‐infected with tuberculosis and HIV‐1 while receiving non‐nucleoside reverse transcriptase inhibitor‐based antiretroviral therapy and rifampicin‐containing anti‐tuberculosis regimen. Southeast Asian Journal of Tropical Medicine and Public Health2011;42(3):651‐8. [PUBMED: 21706943] ">Mankhatitham 2011</a>; <a href="./references#CD004246-bbs2-0027" title="MankhatithamW , LuaengniyomkulA , ManosuthiW . Lipid profile changes in Thai HIV and tuberculosis co‐infected patients receiving non‐nucleoside reverse transcriptase inhibitors‐based antiretroviral therapy. Chotmaihet thangphaet [Journal of the Medical Association of Thailand]2012;95(2):163‐9. [PUBMED: 22435244] ">Mankhatitham 2012</a>; <a href="./references#CD004246-bbs2-0033" title="PadmapriyadarsiniC , BhavaniPK , TangA , KumarH , PonnurajaC , NarendranG , et al. Early changes in hepatic function among HIV‐tuberculosis patients treated with nevirapine or efavirenz along with rifampin‐based anti‐tuberculosis therapy. International Journal of Infectious Diseases2013;17(12):e1154‐9. [PUBMED: 24120216] ">Padmapriyadarsini 2013</a>), 1 was not an RCT(<a href="./references#CD004246-bbs2-0037" title="PuthanakitT , KerrSJ , AnanworanichJ , BunupuradahT , BoonrakP , SirisanthanaV . Pattern and predictors of immunologic recovery in human immunodeficiency virus‐infected children receiving non‐nucleoside reverse transcriptase inhibitor‐based highly active antiretroviral therapy. Pediatric Infectious Disease Journal2009;28(6):488‐92. ">Puthanakit 2009b</a>) and another was a duplicate (<a href="./references#CD004246-bbs2-0038" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Once‐daily nevirapine vs efavirenz in the treatment of HIV‐infected patients with TB: a randomized clinical trial. 16th conference on retroviruses and opportunistic infections. Montreal, Canada, February 8‐11, 2009.. 2009. [PUBMED: 21890776] ">Swaminathan 2009</a>). </p> </section> </section> <section id="CD004246-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias in each included study using the Cochrane 'Risk of bias' assessment tool (<a href="./appendices#CD004246-sec-0103">Appendix 5</a>). We assessed the risk of bias in individual trials across six domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential biases. See the 'Risk of bias' summary (<a href="#CD004246-fig-0002">Figure 2</a>) and 'Risk of bias' graph (<a href="#CD004246-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD004246-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial." data-id="CD004246-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial. </p> </div> </div> </div> <div class="figure" id="CD004246-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD004246-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD004246-sec-0061"> <h4 class="title">Allocation</h4> <section id="CD004246-sec-0062"> <h5 class="title">Generation of allocation sequence</h5> <p>Only five trials reported how the allocation sequence was generated. (<a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). The other included trials did not report how they generated the allocation sequence (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>). </p> </section> <section id="CD004246-sec-0063"> <h5 class="title">Allocation concealment</h5> <p>Only five trials reported that allocation was concealed (<a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). In seven trials, allocation concealment was unclear (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>). </p> </section> </section> <section id="CD004246-sec-0064"> <h4 class="title">Blinding</h4> <p>Ten trials were reported as open‐label studies and we judged them to be at high risk of bias (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>). Only one was blinded (<a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>). <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a> did not report blinding and therefore we considered it to be at unclear risk of bias. </p> </section> <section id="CD004246-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>We judged three trials as having unclear risk of attrition bias (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>). The other nine included trials were at low risk of bias. </p> </section> <section id="CD004246-sec-0066"> <h4 class="title">Selective reporting</h4> <p>One trial did not report all outcomes (<a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>). Two studies did not provide sufficient information to enable us to make a judgement (<a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>). </p> <section id="CD004246-sec-0067"> <h5 class="title">Reporting of baseline data</h5> <p>Two trials, Sow (<a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>) and Mateelli (<a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>,) did not report baseline data, and we considered them as being at unclear risk of bias. </p> </section> </section> <section id="CD004246-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <section id="CD004246-sec-0069"> <h5 class="title">Funding</h5> <p>Eight trials received funding from governmental sources (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>) and were judged as low risk of bias. The 2NN study, <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>, was funded by Boehringer‐Ingelheim. <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a> also received funding from Gilead Sciences, Merck, Sharp &amp; Dome, and Abbott Laboratories. We judged them as high risk of bias. <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a> and <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a> did not report any source of funding. We judged them as unclear risk of bias. </p> </section> <section id="CD004246-sec-0070"> <h5 class="title">Publication bias</h5> <p>We designed our search strategy to detect both published and unpublished studies. We appraised publication bias for our primary outcome of virologic suppression using a funnel plot and found no evidence of publication bias (<a href="./references#CD004246-bbs2-0047" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical research ed.)1997;315(7109):629‐34. [PUBMED: 9310563] ">Egger 1997</a>). See <a href="#CD004246-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD004246-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Efavirenz 600 mg versus Nevirapine all doses, outcome: 1.1 Virological success." data-id="CD004246-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Efavirenz 600 mg versus Nevirapine all doses, outcome: 1.1 Virological success. </p> </div> </div> </div> </section> </section> </section> <section id="CD004246-sec-0071"> <h3 class="title" id="CD004246-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD004246-tbl-0001"><b>Summary of findings for the main comparison</b> 'Summary of findings' table 1</a>; <a href="./full#CD004246-tbl-0002"><b>Summary of findings 2</b> 'Summary of findings' table 2</a> </p> <p>All included trials compared EFV 600 mg once daily to NVP 200 mg twice daily or 400 mg once daily. </p> <p>We performed a primary meta‐analysis to compare EFV 600 mg versus all dosages of NVP. We then conducted subgroup analyses to investigate the effect of NVP dosage (200 mg twice daily versus 400 mg once daily) and concurrent treatment for tuberculosis. </p> <section id="CD004246-sec-0072"> <h4 class="title">Efavirenz 600 mg versus nevirapine at any dosage</h4> <p>These results are summarized in 'Summary of findings' table 1 (<a href="./full#CD004246-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD004246-sec-0073"> <h5 class="title">Virological success</h5> <p>Virological success was comparable in both treatment groups (risk ratio (RR) 1.04, 95% confidence interval (CI) 0.99 to 1.09; 10 trials, 2438 participants; P = 0.11; <a href="./references#CD004246-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD004246-sec-0074"> <h5 class="title">Mortality</h5> <p>There were no differences in mortality between the EFV‐ and NVP‐containing regimens (RR 0.84, 95% CI 0.59 to 1.19; 8 trials, 2317 participants; P = 0.32; <a href="./references#CD004246-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD004246-sec-0075"> <h5 class="title">Progression to AIDS</h5> <p>In both EFV‐ and NVP‐containing regimens progression to AIDS was comparable (RR 1.23, 95% CI 0.72 to 2.11; 5 trials, 2005 participants; P = 0.46). Statistical heterogeneity was moderate (I<sup>2</sup> statistic = 33%, P = 0.22; <a href="./references#CD004246-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD004246-sec-0076"> <h5 class="title">All severe adverse events</h5> <p>Severe adverse events were comparable in both treatment groups (RR 0.91, 95% CI 0.71 to 1.18; 8 trials, 2329 participants; P = 0.48). Statistical heterogeneity was moderate (I<sup>2</sup> statistic = 43%, P = 0.11; <a href="./references#CD004246-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD004246-sec-0077"> <h5 class="title">Discontinuation rate</h5> <p>There was no difference in discontinuation rate between treatment groups (RR 0.93, 95% CI 0.69 to 1.25; 9 trials, 2384 participants; P = 0.62). Statistical heterogeneity was moderate (I<sup>2</sup>statistic = 35%, P = 0.14; <a href="./references#CD004246-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD004246-sec-0078"> <h5 class="title">Change in CD4 count/immunological response</h5> <p>Change in CD4 count was comparable in both EFV‐ and NVP‐containing regimens (MD −3.03; 95% CI −17.41 to 11.35; 9 trials, 1829 participants; P = 0.68). Statistical heterogeneity was moderate (I<sup>2</sup> statistic = 29%, P = 0.19; <a href="./references#CD004246-fig-0010" title="">Analysis 1.6</a>). </p> </section> <section id="CD004246-sec-0079"> <h5 class="title">Treatment failure</h5> <p>Treatment failure was comparable in both treatment groups (RR 0.97, 95% CI 0.76 to 1.24; 5 trials, 737 participants; P = 0.82; <a href="./references#CD004246-fig-0011" title="">Analysis 1.7</a>). </p> </section> <section id="CD004246-sec-0080"> <h5 class="title">Sexual transmission of HIV</h5> <p>None of the included studies reported on this outcome.</p> </section> <section id="CD004246-sec-0081"> <h5 class="title">Development of drug resistance</h5> <p>Four studies (988 participants) reported this outcome. Development of drug resistance was lower in the EFV arm (RR 0.76, 95% CI 0.60 to 0.95; 4 trials, 988 participants; P = 0.02; <a href="./references#CD004246-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD004246-sec-0082"> <h5 class="title">Individual adverse events</h5> <p>Individual comparisons for each of the adverse events: gastrointestinal (<a href="./references#CD004246-fig-0014" title="">Analysis 2.2</a>), pyrexia (<a href="./references#CD004246-fig-0015" title="">Analysis 2.3</a>), raised alkaline phosphatases (<a href="./references#CD004246-fig-0017" title="">Analysis 2.5</a>), elevated amylase (<a href="./references#CD004246-fig-0018" title="">Analysis 2.6</a>), elevated triglycerides (<a href="./references#CD004246-fig-0019" title="">Analysis 2.7</a>), elevated SGOT (<a href="./references#CD004246-fig-0022" title="">Analysis 2.10</a>), elevated SGPT (<a href="./references#CD004246-fig-0023" title="">Analysis 2.11</a>) and elevated cholesterol (<a href="./references#CD004246-fig-0024" title="">Analysis 2.12</a>) did not reveal any differences. Central nervous system adverse events were higher in the EFV arm (RR 4.46, 95% CI 1.65 to 12.03; 6 trials, 2049 participants; P = 0.003). Statistical heterogeneity was moderate (I<sup>2</sup> statistic = 44%, P = 0.13; <a href="./references#CD004246-fig-0013" title="">Analysis 2.1</a>). Participants in the EFV arm were less likely to have raised transaminases than those in the NVP arm (RR 0.52, 95% CI 0.35 to 0.78; 3 trials, 1799 participants; P = 0.001; <a href="./references#CD004246-fig-0016" title="">Analysis 2.4</a>). Participants in the EFV arm were less likely to have neutropenia (RR 0.48, 95% CI 0.28 to 0.82; 3 trials, 1799 participants; P = 0.007; <a href="./references#CD004246-fig-0020" title="">Analysis 2.8</a>). Participants in the EFV arms were also less likely to have a rash (RR 0.58, 95% CI 0.34 to 1.00; 7 trials, 2277 participants; P = 0.05; <a href="./references#CD004246-fig-0021" title="">Analysis 2.9</a>). We have summarized the findings for the individual adverse events in 'Summary of findings' table 2 (<a href="./full#CD004246-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> <section id="CD004246-sec-0083"> <h4 class="title">Subgroup analyses</h4> <section id="CD004246-sec-0084"> <h5 class="title">Hepatitis co‐morbidity</h5> <p>There were insufficient data to explore this subgroup.</p> </section> <section id="CD004246-sec-0085"> <h5 class="title">Concurrent treatment for tuberculosis</h5> <p>There were no significant subgroup effects for tuberculosis treatment: virological success (<a href="./references#CD004246-fig-0025" title="">Analysis 3.1</a>), mortality (<a href="./references#CD004246-fig-0026" title="">Analysis 3.2</a>), progression to AIDS (<a href="./references#CD004246-fig-0027" title="">Analysis 3.3</a>), discontinuation rate (<a href="./references#CD004246-fig-0028" title="">Analysis 3.4</a>). </p> </section> <section id="CD004246-sec-0086"> <h5 class="title">Dosage</h5> <p>We found that mortality was lower in the EFV arm than in the NVP 400 mg subgroup (RR 0.34, 95% CI 0.13 to 0.90; P = 0.03; <a href="./references#CD004246-fig-0030" title="">Analysis 4.2</a>). One study did not report the dosage of NVP used (<a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>), and we excluded it from this analysis. Virological success (<a href="./references#CD004246-fig-0029" title="">Analysis 4.1</a>), progression to AIDS (<a href="./references#CD004246-fig-0031" title="">Analysis 4.3</a>) and discontinuation rate (<a href="./references#CD004246-fig-0032" title="">Analysis 4.4</a>) were similar for both dosages. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004246-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004246-sec-0087"></div> <section id="CD004246-sec-0088"> <h3 class="title" id="CD004246-sec-0088">Summary of main results</h3> <p>Twelve randomized controlled trials (RCTs) that included 3278 participants met the inclusion criteria of this Cochrane Review. </p> <p>There was little or no difference between EFV and NVP in virological success (<i>high quality evidence</i> ), probably little or no difference in mortality (<i>moderate quality evidence</i> ) and progression to AIDS (<i>moderate quality evidence</i> ). We are uncertain whether there is a difference in all severe adverse events (<i>very low quality evidence</i> ). There is probably little or no difference in discontinuation rate (<i>moderate quality evidence</i> ) and change in CD4 count (<i>moderate quality evidence</i> ). There may be little or no difference in treatment failure (<i>low quality evidence</i> ). Development of drug resistance is probably slightly less in the EFV arms (<i>moderate quality evidence</i>). No studies were found that looked at sexual transmission of HIV. </p> <p>When we examined the adverse events individually, EFV probably increased impaired mental function (<i>moderate quality evidence</i> ) but reduced elevated transaminases (<i>high quality evidence</i> ), reduced cases of neutropenia (<i>high quality evidence</i> ), and probably reduced cases of rash (<i>moderate quality evidence</i> ). We found that there may be little or no difference in gastrointestinal adverse events (<i>low quality evidence</i> ), pyrexia (<i>low quality evidence</i> ), raised alkaline phosphatase (<i>low quality evidence</i> ), raised amylase (<i>low quality evidence</i> ) and raised triglycerides (<i>low quality evidence</i> ). There was probably little or no difference in serum glutamic oxaloacetic transaminase (<i>moderate quality evidence</i> ), serum glutamic‐ pyruvic transaminase (<i>moderate quality evidence</i> ) and raised cholesterol (<i>moderate quality evidence</i> ). NVP slightly increases mortality when given once daily (<i>high quality evidence</i>). There were little or no differences in the primary outcomes for patients who were concurrently receiving treatment for tuberculosis. </p> <p>This literature is dominated by the landmark 2NN study, <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>, which found no difference between EFV and NVP in a non‐inferiority randomized open‐label, industry‐funded, four‐arm trial. Overall <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a> accounted for 1007 (31%) of the 3278 participants randomized. </p> <p>We did not conduct subgroup analyses by NRTI combination drugs even though of the nine trials that had a NVP 200 mg twice daily arm (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>); five used a 3TC/AZT (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), one trial used the 3TC/d4Tand switched to the 3TC/AZT backbone in the last year (<a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>), and three trials (<a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>) used at least two NRTI combinations including 3TC/AZT, 3TC/ABC, 3TC/d4T, or ddI/d4T. Moreover, all of the trials using NVP 400 mg once daily had different NRTI combination drugs. None of the included trials reported the outcome of sexual transmission of HIV. The length of follow‐up time, cut‐off point for undetectable viral load, dosage of NVP, and study settings varied greatly. We did not find any statistically significant heterogeneity for any of the key outcomes, and the I<sup>2</sup> statistic value ranged from 0% to 40%. </p> </section> <section id="CD004246-sec-0089"> <h3 class="title" id="CD004246-sec-0089">Overall completeness and applicability of evidence</h3> <p>We identified literature that met the inclusion criteria of this Cochrane Review that clearly highlights the clinical equivalence of EFV and NVP based on RCTs. </p> <p>This update includes studies from a wide variety of settings including a large multicentre trial with participants from the USA, Europe, Australia, Thailand, and South Africa (<a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), but also trials with participants from Mexico (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>), Senegal (<a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>), Cameroon (<a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>), Thailand (<a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>), Spain (<a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>), India (<a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>), USA (<a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>), Mozambique (<a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>) and Botswana (<a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>). These diverse populations support the applicability and generalizability of our findings. </p> <p>Given optimal adherence, EFV, NVP 200 mg, and NVP 400 mg once daily may result in comparable virological suppression. However, there is a increased risk of mortality in the patients receiving the once‐daily NVP regimen. There is insufficient evidence to recommend the use of once daily NVP in regular clinical practice (<a href="./references#CD004246-bbs2-0042" title="CooperCL , vanHeeswijkRPG . Once‐daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Medicine2007;8(1):1‐7. ">Cooper 2007</a>), and our findings do not support its use. </p> </section> <section id="CD004246-sec-0090"> <h3 class="title" id="CD004246-sec-0090">Quality of the evidence</h3> <p>This body of evidence includes twelve RCTs (3278 participants). The main methodological limitation in the included studies was the lack of blinding. Only one study was blinded (<a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a>). In most instances, this did not affect our rating of the quality of evidence for outcomes unlikely to be affected by a lack of blinding such as virological success, mortality and progression to AIDS. In two studies reported as abstracts, risk of bias was unclear in almost all the domains (<a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>). The cut‐off point used to define virological success also differed across studies, but this was related to the quality of the equipment available and did not seem to introduce any heterogeneity in measures of virological success. We did not downgraded for this. We downgraded when adverse events were graded using different scales, the definition of treatment failure varied across studies, industry funded studies contributed most of the data for certain outcomes and confidence intervals were too wide. Overall the quality of the evidence ranged from high to very low. </p> </section> <section id="CD004246-sec-0091"> <h3 class="title" id="CD004246-sec-0091">Potential biases in the review process</h3> <p>We minimized biases in the review process by not limiting the literature search by language, by performing a comprehensive search of databases and conference proceedings, and by contacting experts in the field for unpublished and ongoing studies. However, we were unable to fully appraise the trials published only as abstracts and is it unclear what methodological or data items were not captured in this review. We used a funnel plot and found no evidence of publication bias. </p> </section> <section id="CD004246-sec-0092"> <h3 class="title" id="CD004246-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review that compared EFV to NVP in patients co‐infected with TB found superior virologic suppression in the EFV arm at the 400 copies/mL cut‐off point (but not at the 50 copies/mL cut‐off point). Mortality was comparable, but more participants in the NVP arm discontinued treatment (<a href="./references#CD004246-bbs2-0053" title="JiangHY , ZhangMN , ChenHJ , YangY , DengM , RuanB . Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a systematic review and meta‐analysis. International Journal of Infectious Diseases2014;25:130‐5. [PUBMED: 24911886] ">Jiang 2014</a>). We found comparable effective of EFV and NVP (using all cut‐off points), comparable mortality and no differences in our subgroup analysis of participants on treatment for TB. Another systematic review found EFV to be less likely to lead to virological failure and more likely to induce virological success (<a href="./references#CD004246-bbs2-0059" title="PillayP , FordN , ShubberZ , FerrandRA . Outcomes for efavirenz versus nevirapine‐containing regimens for treatment of HIV‐1 infection: a systematic review and meta‐analysis. PLOS ONE2013;8(7):e68995. [PUBMED: 23894391] ">Pillay 2013</a>). A systematic review of adverse events found EFV to be less likely to be associated with hepatic and cutaneous adverse events, but more likely to be associated with central nervous system adverse events (<a href="./references#CD004246-bbs2-0061" title="ShubberZ , CalmyA , Andrieux‐MeyerI , VitoriaM , Renaud‐ThéryF , ShafferN , et al. Adverse events associated with nevirapine and efavirenz‐based first‐line antiretroviral therapy: a systematic review and meta‐analysis. AIDS (London, England)2013;27(9):1403‐12. [PUBMED: 23343913] ">Shubber 2013</a>). The main difference between these systematic reviews and ours is their use of non‐randomized studies which may lead to differences in estimates. More so, the apparent poorer performance of NVP might also be induced by the once daily 400 mg regimen, which we found to be inferior to EFV with regard to mortality. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004246-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of study screening and selection" data-id="CD004246-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of study screening and selection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial." data-id="CD004246-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD004246-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Efavirenz 600 mg versus Nevirapine all doses, outcome: 1.1 Virological success." data-id="CD004246-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Efavirenz 600 mg versus Nevirapine all doses, outcome: 1.1 Virological success. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 1 Virological success." data-id="CD004246-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 1 Virological success.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 2 Mortality." data-id="CD004246-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 2 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 3 Progression to AIDS." data-id="CD004246-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 3 Progression to AIDS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 4 All severe adverse events." data-id="CD004246-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 4 All severe adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 5 Discontinuation rate." data-id="CD004246-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 5 Discontinuation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 6 Change in CD4 count." data-id="CD004246-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 6 Change in CD4 count. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 7 Treatment failure." data-id="CD004246-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 7 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 8 Development of drug resistance." data-id="CD004246-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Efavirenz 600 mg versus nevirapine all doses, Outcome 8 Development of drug resistance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 1 Severe adverse events: central nervous system." data-id="CD004246-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 1 Severe adverse events: central nervous system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 2 Severe adverse events: gastrointestinal tract." data-id="CD004246-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 2 Severe adverse events: gastrointestinal tract. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 3 Severe adverse events: pyrexia." data-id="CD004246-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 3 Severe adverse events: pyrexia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 4 Severe adverse events: elevated transaminases." data-id="CD004246-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 4 Severe adverse events: elevated transaminases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 5 Severe adverse events: elevated alkaline phosphatase." data-id="CD004246-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 5 Severe adverse events: elevated alkaline phosphatase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 6 Severe adverse events: elevated amylase." data-id="CD004246-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 6 Severe adverse events: elevated amylase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 7 Severe adverse events: elevated triglycerides." data-id="CD004246-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 7 Severe adverse events: elevated triglycerides. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 8 Severe adverse events: neutropenia." data-id="CD004246-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 8 Severe adverse events: neutropenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 9 Severe adverse events: rash." data-id="CD004246-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 9 Severe adverse events: rash. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 10 Severe adverse events: elevated SGOT." data-id="CD004246-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 10 Severe adverse events: elevated SGOT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 11 Severe adverse events: elevated SGPT." data-id="CD004246-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 11 Severe adverse events: elevated SGPT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 12 Severe adverse events: elevated cholesterol." data-id="CD004246-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Efavirenz 600 mg versus nevirapine all doses: adverse events, Outcome 12 Severe adverse events: elevated cholesterol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments, Outcome 1 Virological success." data-id="CD004246-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments, Outcome 1 Virological success. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments, Outcome 2 Mortality." data-id="CD004246-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments, Outcome 2 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments, Outcome 3 Progression to AIDS." data-id="CD004246-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments, Outcome 3 Progression to AIDS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments, Outcome 4 Discontinuation rate." data-id="CD004246-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments, Outcome 4 Discontinuation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Efavirenz 600 mg versus nevirapine: subgroup analyses for dosage, Outcome 1 Virological success." data-id="CD004246-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Efavirenz 600 mg versus nevirapine: subgroup analyses for dosage, Outcome 1 Virological success. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Efavirenz 600 mg versus nevirapine: subgroup analyses for dosage, Outcome 2 Mortality." data-id="CD004246-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Efavirenz 600 mg versus nevirapine: subgroup analyses for dosage, Outcome 2 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Efavirenz 600 mg versus nevirapine: subgroup analyses for dosage, Outcome 3 Progression to AIDS." data-id="CD004246-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Efavirenz 600 mg versus nevirapine: subgroup analyses for dosage, Outcome 3 Progression to AIDS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004246-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/urn:x-wiley:14651858:media:CD004246:CD004246-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_t/tCD004246-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Efavirenz 600 mg versus nevirapine: subgroup analyses for dosage, Outcome 4 Discontinuation rate." data-id="CD004246-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Efavirenz 600 mg versus nevirapine: subgroup analyses for dosage, Outcome 4 Discontinuation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/media/CDSR/CD004246/image_n/nCD004246-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004246-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">'Summary of findings' table 1</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Efavirenz (600 mg) versus nevirapine (all doses) for three‐drug combination therapy with two nucleoside‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐</b> naïve<b>individuals</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> antiretroviral‐naïve individuals<br/> <b>Setting:</b> all settings<br/> <b>Intervention:</b> efavirenz 600 mg<br/> <b>Comparison:</b> nevirapine all doses (400 mg once daily and 400 mg twice daily) as part of a three‐drug combination therapy with two NRTIs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (RCTs)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with nevirapine all doses</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with efavirenz 600 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Virological success</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>688 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>715 per 1000<br/> (681 to 750) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/> (0.99 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2438<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> high<sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/> (38 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84<br/> (0.59 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2317<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>4,5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to AIDS</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<br/> (29 to 86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.23<br/> (0.72 to 2.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>5,6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All severe adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000<br/> (162 to 285) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91<br/> (0.71 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2329<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>5,7,8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000<br/> (122 to 220) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.93<br/> (0.69 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2384<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in CD4 count</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in CD4 count was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.03 lower<br/> (17.41 lower to 11.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1829<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>5,9,10,11</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>242 per 1000<br/> (189 to 309) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/> (0.76 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>737<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>12,13</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations</b>: CI: confidence interval; RR: risk ratio; OR: odds ratio; RCT: randomized controlled trial; GRADE: Grading of Recommendations Assessment, Development and Evaluation; MD: mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Three trials used a cut‐off point of 400 copies/mL (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>), but we did not downgrade for this.<br/> <sup>2</sup>Nine trials were open‐label (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), but we did not downgrade for this.<br/> <sup>3</sup>Two trials were industry‐funded (<a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), but we did not downgrade for this.<br/> <sup>4</sup>Seven trials were open‐label but we did not downgrade for this (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>).<br/> <sup>5</sup>We downgraded by 1 for imprecision due to wide CIs including appreciable harm or benefit.<br/> <sup>6</sup>Four trials were open‐labelled but we did not downgrade for this (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>)<br/> <sup>7</sup>Six trials were open‐label (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). We downgraded by 1 for this.<br/> <sup>8</sup>Trials did not report the same adverse events and used different severity scales. We downgraded by 1 for this.<br/> <sup>9</sup>Seven of the trials were open‐label but we did not downgrade for this (<a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a>; <a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a>; <a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>).<br/> <sup>10</sup>In one trial, the risk of bias was unclear (<a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>).<br/> <sup>11</sup>One trial had industry funding (<a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), but we did not downgrade for this.<br/> <sup>12</sup>All trials were open‐labelled but we did not downgrade for this.<br/> <sup>13</sup>Each included trial that reported this outcome defined treatment failure differently. We downgraded by 2. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">'Summary of findings' table 1</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004246-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">'Summary of findings' table 2</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Efavirenz (600 mg) versus nevirapine (all doses): adverse events for three‐drug combination therapy with two nucleoside‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐</b> naïve<b>individuals</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> antiretroviral‐naïve individuals<br/> <b>Setting:</b> all settings<br/> <b>Intervention:</b> efavirenz 600 mg<br/> <b>Comparison:</b> nevirapine all doses (400 mg once daily and 400 mg twice daily) as part of a three‐drug combination therapy with two NRTIs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (RCTs)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with nevirapine all doses: adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with efavirenz 600 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: central nervous system</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (2 to 18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.46<br/> (1.65 to 12.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2049<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: gastrointestinal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/> (9 to 22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76<br/> (0.48 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2049<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: pyrexia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.15 to 2.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1799<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: raised transaminases</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1000<br/> (90 to 201) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.52<br/> (0.35 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1299<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> high<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: raised alkaline phosphatase</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (2 to 29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.17 to 2.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1007<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: raised amylase</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (10 to 38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.40<br/> (0.72 to 2.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1071<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: raised triglycerides</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (3 to 21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10<br/> (0.39 to 3.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1071<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: neutropenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (11 to 31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.48<br/> (0.28 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1799<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> high<sup>3,8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: rash</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>229 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000<br/> (78 to 229) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/> (0.34 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2277<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>2,9</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: serum glutamic oxaloacetic transaminase (SGOT)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean severe adverse events: SGOT was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.3 higher<br/> (2.06 lower to 8.66 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events: serum glutamic‐ pyruvic transaminase (SGPT)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean severe adverse events: SGPT was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 5.7 higher<br/> (4.23 lower to 15.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Raised cholesterol</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172 per 1000<br/> (21 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 6.03<br/> (0.75 to 48.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations</b>: CI: confidence interval; RR: risk ratio; OR: odds ratio; RCT: randomized controlled trial; GRADE: Grading of Recommendations Assessment, Development and Evaluation; MD: mean difference; SGOT: glutamic oxaloacetic transaminase; SGPT: serum glutamic‐ pyruvic transaminase </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Five trials (<a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>) were open‐label. One trial did not report blinding (<a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>). We downgraded by 1 for this.<br/> <sup>2</sup>We downgraded by 1 for very wide CIs.<br/> <sup>3</sup>All trials were open‐label.<br/> <sup>4</sup>Two trials (<a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>) were open label. <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a> was industry‐funded. We did not downgrade for this.<br/> <sup>5</sup>Data from one open‐label industry‐funded study (<a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). We downgraded by 1 for this.<br/> <sup>6</sup>Both trials were open‐label (<a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>), but we did not downgrade for this.<br/> <sup>7</sup>Most data came from one industry‐funded trial (<a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>). We downgraded one point for this.<br/> <sup>8</sup>We upgraded by 1 due to the large effect.<br/> <sup>9</sup>Six studies were open‐label (<a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a>; <a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a>; <a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a>; <a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a>; <a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a>; <a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a>). We did not downgrade for this. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">'Summary of findings' table 2</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004246-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Location</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> NVP dosage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> NRTI combination drugs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Co‐infection with tuberculosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Virological success cut‐off point</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0001" title="Ayala GaytánJJ , Zapata de La GarzaER , Chávez GarcíaM , Valdovinos ChávezSB . [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV‐infected antiretroviral‐naïve patients]. Medicina Interna de México2004;20(1):24‐33. [CN‐00641209] ">Ayala Gaytán 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mexico</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZT 300 mg and 3TC 150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 400 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0002" title="BonnetM , BhattN , BaudinE , SilvaC , MichonC , TaburetAM , et al. Nevirapine versus efavirenz for patients co‐infected with HIV and tuberculosis: a randomised non‐inferiority trial. Lancet Infectious diseases2013;13(4):303‐12. [PUBMED: 23433590] ">Bonnet 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mozambique</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3TC and d4T/AZT<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0003" title="LandmanR , Koulla‐ShiroS , SowPS , NgolleM , DialloMB , GuèyeNF , et al. Evaluation of four tenofovir‐containing regimens as first‐line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy2014;19(1):51‐9. [PUBMED: 23970206] ">Landman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cameroon and Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TDF 300 mg and FTC 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0004" title="ManosuthiW , SungkanuparphS , TantanathipP , LueangniyomkulA , MankatithamW , PrasithsirskulW , et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse‐transcriptase inhibitor‐based regimens in HIV‐infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases2009;48(12):1752‐9. [PUBMED: 19438397] ">Manosuthi 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3TC 150 mg and D4T 30 or 40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0005" title="MateelliA , KouandaS , SaleriN , OuedraogoG . Efficacy and safety of nevirapine‐ vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3‐16 March, 2013. Atlanta, USA, 2013:Abstract 47462. ">Mateelli 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Burkina Faso</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D4T and 3TC<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0006" title="NúñezM , SorianoV , Martin‐CarboneroL , BarriosA , BarreiroP , BlancoF , et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open‐label study in HIV‐infected naïve individuals. HIV Clinical Trials2002;3(3):186‐94. [PUBMED: 12032877] ">Núñez 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D4T 40 mg and DDI 400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0007" title="SinhaS , RaghunandanP , ChandrashekharR , SharmaSK , KumarS , DhooriaS , et al. Nevirapine versus efavirenz‐based antiretroviral therapy regimens in antiretroviral‐naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases2013;13:482. [PUBMED: 24134449] ">Sinha 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZT, d4T, 3TC<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 400 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0008" title="SowPG , BadianeM , DialloPD , LoI , NdiayeB , GayeAM . Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13‐18 August, 2006. Toronto, Canada, 2006. ">Sow 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZT 300 mg and 3TC 150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0009" title="SwaminathanS , PadmapriyadarsiniC , VenkatesanP , NarendranG , Ramesh KumarS , IliayasS , et al. Efficacy and safety of once‐daily nevirapine‐ or efavirenz‐based antiretroviral therapy in HIV‐associated tuberculosis: a randomized clinical trial. Clinical infectious disease2011;53(7):716‐724. ">Swaminathan 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DDI 250 mg or 400 mg and 3TC 300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0010" title="van denBerg‐WolfM , HullsiekKH , PengG , KozalMJ , NovakRM , ChenL , et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long‐term comparison of efavirenz‐based versus nevirapine‐based antiretroviral regimens as initial therapy in HIV‐1‐infected persons. HIV Clinical Trials2008;9(5):324‐36. [PUBMED: 18977721] ">van den Berg‐Wolf 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC/3TC, DDI/d4T, AZT/3TC, d4T/3TC<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0011" title="vanLethF , PhanuphakP , RuxrungthamK , BaraldiE , MillerS , GazzardB , et al. Comparison of first‐line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open‐label trial, the 2NN Study. Lancet2004;363(9417):1253‐63. [PUBMED: 15094269] ">van Leth 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>North/South America, Australia, Europe, South Africa, and Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg twice daily and 400 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D4T 40 mg and 3TC 150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50 copies/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004246-bbs2-0012" title="WesterCW , ThomasAM , BussmannH , MoyoS , MakhemaJM , GaolatheT , et al. Non‐nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy‐treated adults in Botswana. AIDS (London, England)2010;24 Suppl 1:S27‐36. [PUBMED: 20023437] ">Wester 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botswana</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZT or d4T/3TC or DDI<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Dosage not specified.<br/> Abbreviations: NRTI: Nucleoside Reverse Transcriptase Inhibitor; ART: antiretroviral therapy; AZT: zidovudine; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; DDI: didanosine; ABC: abacavir; FTC: Emtricitabine; TDF: Tenofovir. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/full#CD004246-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004246-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Efavirenz 600 mg versus nevirapine all doses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Virological success <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.99, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.59, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression to AIDS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.72, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All severe adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.71, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Discontinuation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.69, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change in CD4 count <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.03 [‐17.41, 11.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.76, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Development of drug resistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.60, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Efavirenz 600 mg versus nevirapine all doses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004246-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Efavirenz 600 mg versus nevirapine all doses: adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Severe adverse events: central nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.46 [1.65, 12.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Severe adverse events: gastrointestinal tract <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.48, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Severe adverse events: pyrexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.15, 2.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Severe adverse events: elevated transaminases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.35, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Severe adverse events: elevated alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.17, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Severe adverse events: elevated amylase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.72, 2.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Severe adverse events: elevated triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.39, 3.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Severe adverse events: neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.28, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Severe adverse events: rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.34, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Severe adverse events: elevated SGOT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [‐2.06, 8.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Severe adverse events: elevated SGPT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [‐4.23, 15.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Severe adverse events: elevated cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.03 [0.75, 48.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Efavirenz 600 mg versus nevirapine all doses: adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004246-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Virological success <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.99, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Concurrent treatment for TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.99, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 No treatment for TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.95, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.59, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Concurrent treatment for TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.40, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 No treatment for TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.62, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression to AIDS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.72, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Concurrent treatment for TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.62, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 No treatment for TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.44, 5.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Discontinuation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.69, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Concurrent treatment for TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.59, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 No treatment for TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.63, 1.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004246-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Efavirenz 600 mg versus nevirapine: subgroup analyses for dosage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Virological success <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.99, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Nevirapine 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.97, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Nevirapine 400 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.94, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.57, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nevirapine 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.64, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Nevirapine 400 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.13, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression to AIDS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.76, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nevirapine 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.75, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Nevirapine 400 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.25, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Discontinuation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.66, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Nevirapine 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.71, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Nevirapine 400 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.40, 1.57]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Efavirenz 600 mg versus nevirapine: subgroup analyses for dosage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004246.pub4/references#CD004246-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004246.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004246-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004246-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD004246-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004246\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004246\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004246\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004246\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004246\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004246.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004246.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004246.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004246.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004246.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719137688"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004246.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719137692"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004246.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de16bdb0e1be4',t:'MTc0MDcxOTEzNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 